Common use of Records; Reports; Deliverables Clause in Contracts

Records; Reports; Deliverables. UHN and the Principal Investigators shall keep and maintain complete and accurate written records of the performance of the Additional Research Program, including, without limitation, records of all data, reports, deliverables and inventions. In addition to the informal communication noted above, UHN will provide to MBI by email the following reports and deliverables: (a) within two (2) weeks after the end of each quarter during the Additional Research Program, a progress report (approximately five pages) summarizing the work completed during the preceding quarter, including, among other relevant matters, details of the activities undertaken and the accomplishments achieved and challenges faced, progress made in light of the requirements for Successful Completion and the deliverables outlined in Schedule A in respect of the particular Phase of the Additional Research Program and the development of any Intellectual Property. The Principal Investigators (and their research team, where applicable) and MBI will, as soon as reasonably practicable after the receipt by MBI of each report, convene a meeting by either by conference or video whereby UHN will present to MBI on the contents of the report and a discussion will ensue; and (b) within two (2) weeks after the completion of each Phase of the Additional Research Program: (i) a detailed report (approximately five to seven pages) setting out the results of the research completed during the relevant Phase compared to the deliverables outlined in the Additional Research Program (and, in particular, evidence of whether or not UHN has achieved Successful Completion described in Section 2.5 above for the Phase), and the development of any Intellectual Property; and (ii) copies of all Intellectual Property forming a part of the Additional Licensed Technology arising from the relevant Phase of the Additional Research Program, all in a form and with content reasonably satisfactory to MBI as required to enable MBI’s reasonably competent staff to further develop and commercialize such technology, including the transfer of such technology to a third party. The results outlined in the report shall be consistent in detail with those found in the publication, in respect of the Licensed Technology, entitled “Three-gene prognostic classifier for early-stage non-small-cell lung cancer”, ▇▇▇, K., et al. (2007), Journal of Clinical Oncology. The Principal Investigators (and their research team, where applicable) and MBI will, as soon as reasonably practicable after the receipt by MBI of each detailed report under this subsection, convene an in-person meeting at UHN’s facilities whereby UHN will make a presentation to MBI on the contents of the report and a discussion will ensue during which UHN will address technical issues raised by MBI regarding the information so provided.

Records; Reports; Deliverables. UHN and the Principal Investigators shall keep and maintain complete and accurate written records of the performance of the Additional Research Program, including, without limitation, records of all data, reports, deliverables and inventions. In addition to the informal communication noted above, UHN will provide to MBI by email the following reports and deliverables: (a) within two (2) weeks after the end of each quarter during the Additional Research Program, a progress report (approximately five pages) summarizing the work completed during the preceding quarter, including, among other relevant matters, details of the activities undertaken and the accomplishments achieved and challenges faced, progress made in light of the requirements for Successful Completion and the deliverables outlined in Schedule A in respect of the particular Phase of the Additional Research Program and the development of any Intellectual Property. The Principal Investigators (and their research team, where applicable) and MBI will, as soon as reasonably practicable after the receipt by MBI of each report, convene a meeting by either by conference or video whereby UHN will present to MBI on the contents of the report and a discussion will ensue; and (b) within two (2) weeks after the completion of each Phase of the Additional Research Program: (i) a detailed report (approximately five to seven pages) setting out the results of the research completed during the relevant Phase compared to the deliverables outlined in the Additional Research Program (and, in particular, evidence of whether or not UHN has achieved Successful Completion described in Section 2.5 above for the Phase), and the development of any Intellectual Property; and (ii) copies of all Intellectual Property forming a part of the Additional Licensed Technology arising from the relevant Phase of the Additional Research Program, all in a form and with content reasonably satisfactory to MBI as required to enable MBI’s reasonably competent staff to further develop and commercialize such technology, including the transfer of such technology to a third party. The results outlined in the report shall be consistent in detail with those found in the publication, in respect of the Licensed Technology, entitled “Three-gene prognostic classifier for early-stage non-small-cell lung cancer”, ▇▇▇, K., et al. (2007), Journal of Clinical Oncology. The Principal Investigators (and their research team, where applicable) and MBI will, as soon as reasonably practicable after the receipt by MBI of each detailed report under this subsection, convene an in-person meeting at UHN’s facilities whereby UHN will make a presentation to MBI on the contents of the report and a discussion will ensue during which UHN will address technical issues raised by MBI regarding the information so provided.